Skip to contents

NCA output to pdf file

pdfNCA.Rd

This output NCA result in a pdf file.

Usage

pdfNCA(fileName = "Temp-NCA.pdf", concData, key = "Subject", colTime = "Time", 
       colConc = "conc", dose = 0, adm = "Extravascular", dur = 0, 
       doseUnit = "mg", timeUnit = "h", concUnit = "ug/L", down="Linear", 
       R2ADJ = 0, MW = 0, SS = FALSE, iAUC = "", excludeDelta = 1, UsePoints = NULL)

Arguments

fileName

file name to save

concData

concentration data table

key

column names of concData to be shown in the output table

colTime

column name for time

colConc

column name for concentration

dose

administered dose, a scalar or a vector

adm

one of "Bolus" or "Infusion" or "Extravascular" to indicate drug administration mode

dur

duration of infusion, a scalar or a vector

doseUnit

unit of dose

timeUnit

unit of time

concUnit

unit of concentration

down

either of "Linear" or "Log" to indicate the way to calculate AUC and AUMC

R2ADJ

Minimum adjusted R-square value to determine terminal slope automatically

MW

molecular weight of drug

SS

if steady-state, this should be TRUE. AUCLST (AUClast) is used instead of AUCIFO (AUCinf) for the calculation of Vz (VZFO, VZO), CL (CLFO, CLO), and Vdss (VSSO).

iAUC

interval AUC information in a dataframe with "Name", "Start", and "End" columns

excludeDelta

Improvement of R2ADJ larger than this value could exclude the last point. Default value 1 is for the compatibility with other software. Author recommends to use excludeDelta option with about 0.3.

UsePoints

A list of length equal to the number of subjects/NCAs. Each element is a vector of indices of points to calculate terminal slope for the corresponding subject. Values of use points should not be zero. Use only when automatic determination is not satisfactory. If this is used, R2ADJ option is ignored.

Value

CMAX

maximum concentration, Cmax

CMAXD

dose normalized Cmax, CMAX / Dose, Cmax / Dose

TMAX

time of maximum concentration, Tmax

TLAG

time to observe the first non-zero concentration, for extravascular administration only

CLST

last positive concentration observed, Clast

CLSTP

last positive concentration predicted, Clast_pred

TLST

time of last positive concentration, Tlast

LAMZHL

half-life by lambda z, ln(2)/LAMZ

LAMZ

lambda_z negative of best fit terminal slope

LAMZLL

earliest time for LAMZ

LAMZUL

last time for LAMZ

LAMZNPT

number of points for LAMZ

CORRXY

correlation of log(concentration) and time

R2

R-squared

R2ADJ

R-squared adjusted

C0

back extrapolated concentration at time 0, for bolus intravascular administration only

AUCLST

AUC from 0 to TLST

AUCALL

AUC using all the given points, including trailing zero concentrations

AUCIFO

AUC infinity observed

AUCIFOD

AUCIFO / Dose

AUCIFP

AUC infinity predicted using CLSTP instead of CLST

AUCIFPD

AUCIFP / Dose

AUCPEO

AUC % extrapolation observed

AUCPEP

AUC % extrapolated for AUCIFP

AUCPBEO

AUC % back extrapolation observed, for bolus IV administration only

AUCPBEP

AUC % back extrapolation predicted with AUCIFP, for bolus IV administration only

AUMCLST

AUMC to the TLST

AUMCIFO

AUMC infinity observed using CLST

AUMCIFP

AUMC infinity determined by CLSTP

AUMCPEO

AUMC % extrapolated observed

AUMCPEP

AUMC % extrapolated predicted

MRTIVLST

mean residence time (MRT) to TLST, for intravascular administration

MRTIVIFO

mean residence time (MRT) infinity using CLST, for intravascular administration

MRTIVIFP

mean residence time (MRT) infinity using CLSTP, for intravascular administration

MRTEVLST

mean residence time (MRT) to TLST, for extravascular administration

MRTEVIFO

mean residence time (MRT) infinity using CLST, for extravascular administration

MRTEVIFP

mean residence time (MRT) infinity using CLSTP, for extravascular administration

VZO

volume of distribution determined by LAMZ and AUCIFO, for intravascular administration

VZP

volume of distribution determined by LAMZ and AUCIFP, for intravascular administration

VZFO

VZO for extravascular administration, VZO/F, F is bioavailability

VZFP

VZP for extravascular administration, VZP/F, F is bioavailability

CLO

clearance using AUCIFO, for intravascular administration

CLP

clearance using AUCIFP, for intravascular administration

CLFO

CLO for extravascular administration, CLO/F, F is bioavailability

CLFP

CLP for extravascular administration, CLP/F, F is bioavailability

VSSO

volume of distribution at steady state using CLST, for intravascular administration only

VSSP

volume of distribution at stead state using CLSTP, for intravascular administration only

Author

Kyun-Seop Bae <k@acr.kr>

See also

help, txtNCA, rtfNCA

Examples

#pdfNCA(fileName="NCA-Theoph.pdf", Theoph, key="Subject", colTime="Time", 
#       colConc="conc", dose=320, doseUnit="mg", timeUnit="h", concUnit="mg/L")
#pdfNCA(fileName="NCA-Theoph.pdf", Theoph, key=c("Subject", "Wt"), colTime="Time",
#       colConc="conc", dose=320, doseUnit="mg", timeUnit="h", concUnit="mg/L")
#pdfNCA(fileName="NCA-Indometh.pdf", Indometh, key="Subject", colTime="time", 
#       colConc="conc", adm="Infusion", dur=0.5, dose=25, doseUnit="mg", 
#       timeUnit="h", concUnit="mg/L")